This HTML5 document contains 241 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
phttp://www.wikidata.org/prop/
wikibasehttp://wikiba.se/ontology#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q38956663
rdf:type
wikibase:Item
schema:description
2017 nî lūn-bûn scienca artikolo artikull shkencor wissenschaftlicher Artikel artigo científico tieteellinen artikkeli article científic vitenskapelig artikkel مقالة علمية نشرت في 10 فبراير 2017 2017年論文 научная статья 2017年论文 scientific article published on 10 February 2017 vitskapeleg artikkel 2017年論文 bài báo khoa học vedecký článok 2017年论文 naučni članak 2017年论文 tudományos cikk 2017年论文 мақолаи илмӣ article scientific artigo científico artikel ilmiah bilimsel makale სამეცნიერო სტატია artículo científico publicado en 2017 2017年の論文 научна статия 2017 թվականի փետրվարի 10-ին հրատարակված գիտական հոդված artikulong pang-agham 2017年论文 บทความทางวิทยาศาสตร์ scientific article published on 10 February 2017 научни чланак artykuł naukowy 2017年論文 artículu científicu espublizáu en 2017 научни чланак vědecký článek 2017年論文 наукова стаття, опублікована в лютому 2017 article scientifique teaduslik artikkel ১০ ফেব্রুয়ারি ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ מאמר מדעי 2017年论文 vetenskaplig artikel scientific article published on 10 February 2017 2017年論文 articolo scientifico 2017년 논문 videnskabelig artikel wetenschappelijk artikel artigo científico articol științific επιστημονικό άρθρο
p:P577
wds:Q38956663-B94825FE-BD1B-44A7-A223-28809C5EBB71
wdt:P577
2017-02-11T00:00:00Z
p:P407
wds:Q38956663-DF4120F5-D233-461B-8082-B0475AC8D377
wdt:P407
wd:Q1860
p:P2860
wds:Q38956663-035AA522-413F-43CA-B020-142890BB7947 wds:Q38956663-2918061B-301C-4B2A-9C63-30259426B528 wds:Q38956663-41546E26-80EF-4465-B8E9-A462C522E218 wds:Q38956663-CC8BED33-EF6D-46DD-BD09-6B963C14995A wds:Q38956663-17CD2913-1945-4F30-82D2-DB69357AC6FF wds:Q38956663-1BED96D1-DF41-489A-9913-89D05B32BDA2 wds:Q38956663-1E2423D8-B2A4-4248-8945-F30BF2E0C250 wds:Q38956663-1FFB7EAC-2A24-476F-858F-104E808F4195 wds:Q38956663-B9CB078B-73E7-4DBB-806E-553EBE1696C1 wds:Q38956663-F2698FEE-F6BC-4964-B834-48832CCF32F5 wds:Q38956663-F894294C-BB34-4B93-AE84-9F0F3683E499 wds:Q38956663-E68EC6D4-920A-4EE7-8BB3-F947CE410E4E wds:Q38956663-57F6F67F-442F-4B94-944B-D8C78EF4180E wds:Q38956663-612CEAD2-151C-4488-BF00-65B7FB7D1CD3 wds:Q38956663-4A1E6C1A-6874-414A-912A-7B423B209838 wds:Q38956663-4F4852B9-2738-46E8-B4A3-FFD61648B20C wds:Q38956663-8AB2551A-7AE4-4C99-9469-78102137F253 wds:Q38956663-95169186-AC95-475C-8C8C-2B0B2A974FBF wds:Q38956663-9E1735C9-AF49-4F50-A7FD-DF3BB96643B9 wds:Q38956663-79B5CB23-1F2D-4CFF-8023-D0CD076F4751 wds:Q38956663-7CD19333-7E0E-48C9-A2EC-869AA9CA3A82 wds:Q38956663-86B46B6A-98E3-4E2C-B69E-3F76A749792B
wdt:P2860
wd:Q42214388 wd:Q24605493 wd:Q31115496 wd:Q37725909 wd:Q40821569 wd:Q53078951 wd:Q52149517 wd:Q29616119 wd:Q45814039 wd:Q30746509 wd:Q28278620 wd:Q22252938 wd:Q38619696 wd:Q83661349 wd:Q33381736 wd:Q48922719 wd:Q56873132 wd:Q41459651 wd:Q28271008 wd:Q28270998 wd:Q30249781 wd:Q30053056
p:P2093
wds:Q38956663-743FD039-DD6E-4E0C-B307-C612EA4799DF wds:Q38956663-72185E5F-0017-438C-896C-6D8977A57746 wds:Q38956663-34D044F1-5F62-4B3A-AD2A-353FACF2146A wds:Q38956663-2E2D7EA3-64EB-4A93-B0A0-80BCDF3AB0F6 wds:Q38956663-5C464BB3-0C32-4C6E-8FC6-78D0C4FC15DC wds:Q38956663-59F783E1-B9C6-47CA-AFC7-73ABBCDA3DB6 wds:Q38956663-24DADB5C-82DD-4A17-9A4D-99BDE09E3703 wds:Q38956663-4D2100FC-43DA-40E2-82E1-8A2836E3A719 wds:Q38956663-14CAB340-5B13-45A4-9B58-DA816F7E08E2 wds:Q38956663-4C022727-1AEB-4FDA-A691-669259DCF8C2 wds:Q38956663-45C57D9C-8AB5-45FA-A065-2029BAFAA10A wds:Q38956663-132FB196-75A8-438D-B017-A7A41C7869C8 wds:Q38956663-05938582-AAA5-4E19-A167-298279C17C26 wds:Q38956663-F4CC0D01-1334-4F5F-9E29-9F79A282F2E7 wds:Q38956663-EB5E8D9F-2B13-493E-8194-EFCFB49EB669 wds:Q38956663-D7BB8E2C-B1ED-4847-ADF5-D5EBFD3FD747 wds:Q38956663-D534CFC3-7E2B-4A8B-B476-B6902784FAE6 wds:Q38956663-CD513EC6-32F1-4378-8600-33E87B68F7BE wds:Q38956663-C9BF1BFE-2F87-4BAA-B253-AFA0FFE87315 wds:Q38956663-C9F4B1C2-8B99-4712-A45A-800CA0446435 wds:Q38956663-C900060C-06EF-43EE-8571-0C23A8EFF2A6 wds:Q38956663-BAA28800-CF0F-4B3B-A71B-EB4F209ABD9A wds:Q38956663-C1E44486-87F5-4916-8077-62CD20473C11 wds:Q38956663-B54B5A33-1BDD-4FC4-8A06-23F536A37D73 wds:Q38956663-99318D67-8266-451E-B130-741D969EDB6E wds:Q38956663-92C87B3B-2F91-4A01-950E-85ABC0F87492 wds:Q38956663-918B0C11-CDEF-44D3-A148-437BA5881676
wdt:P2093
François Grand'Maison Radek Ampapa Eva Havrdova Christopher McGuigan Cavit Boz Edgardo Cristiano Suzanne Hodgkinson Csilla Rozsa Magdolna Simo Alasdair Coles Cristina Ramo Roberto Bergamaschi Marc Girard Tunde Csepany Tim Spelman Javier Olascoaga Freek Verheul Jeannette Lechner-Scott Raymond Hupperts Franco Granella Owen Pearson Mark Willis Neil Robertson Alastair Wilkins MSBase Study Group Daniele Spitaleri Murat Terzi
rdfs:label
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
skos:prefLabel
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
schema:name
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
p:P50
wds:Q38956663-23333998-D8F8-416F-8BEF-0D032A9CE5A6 wds:Q38956663-253D5A26-FFF0-4A49-9A3C-5B3820A24382 wds:Q38956663-3E088B86-A957-46C6-B1CB-04D79165FA75 wds:Q38956663-40B36D18-93B7-4880-871B-928DFA2FD76A wds:Q38956663-2C9238A7-770B-44C9-8E1A-48F3BF2E5B63 wds:Q38956663-0D564DBD-F902-462E-BF66-F4894F835AD8 wds:Q38956663-DA21D497-4F8B-4590-94D6-899F47001B0A wds:Q38956663-FF001BD2-07FD-4A00-BE5A-9224D9C71D9E wds:Q38956663-E753A28B-C389-469B-A00D-9AEB4EC62D41 wds:Q38956663-F0DE59A0-00C1-471A-A89B-CA13FFC18A98 wds:Q38956663-A97051F8-E6AB-42DE-8B1F-5B0AE7FE5070 wds:Q38956663-B6038030-50C6-4254-BAAD-AC664EA894EC wds:Q38956663-B6DF17BB-F44E-41AE-BFD3-DE9E2E9B64BC wds:Q38956663-C275D844-9D90-4C76-B76E-6DA0E6747811 wds:Q38956663-C63554C8-8F3E-4F21-B1D4-2AB3C827BF8B wds:Q38956663-86917005-E643-4BA1-B6A2-56DB4ADA9C3A wds:Q38956663-767033AB-8617-47A3-9B98-117E5776A5E9 wds:Q38956663-97A73B69-3011-4409-B599-1A2665F674FF wds:Q38956663-A208A568-CA5D-4126-A551-A81A467AF57B wds:Q38956663-4DC9A6BE-F7E7-43AD-8998-D80C558A44E3 wds:Q38956663-50D3892C-0E92-4C7A-A5DA-BA390BFE0BEA wds:Q38956663-4760142A-F972-4D73-A6DA-901F04320ACA wds:Q38956663-6B0344C1-5DB2-425E-9A37-41B6CE75D323 wds:Q38956663-52C7F9FD-A740-4A63-81AE-3D3AD1240711
wdt:P50
wd:Q41721881 wd:Q49164715 wd:Q96026041 wd:Q41721868 wd:Q41721863 wd:Q57203529 wd:Q57081847 wd:Q66904917 wd:Q113488611 wd:Q37842212 wd:Q38800130 wd:Q38800109 wd:Q56394627 wd:Q39885017 wd:Q43496348 wd:Q43112137 wd:Q87946650 wd:Q56516260 wd:Q79652575 wd:Q42774134 wd:Q41721876 wd:Q114425870 wd:Q41721872 wd:Q86391593
p:P1476
wds:Q38956663-DD011EC7-A135-481A-AE02-1126AE1FB137
wdt:P1476
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
p:P304
wds:Q38956663-6BF5DB53-80DE-4741-869A-8CC1C55CD81A
wdt:P304
271-281
p:P31
wds:Q38956663-FF702C4C-F7D4-4B8F-A3FA-1A1EAD380839
wdt:P31
wd:Q13442814
p:P921
wds:Q38956663-56018A58-41A3-4B91-955F-9D3C2F6B53A2
wdt:P921
wd:Q18555066
p:P698
wds:Q38956663-5C1B44A0-8CD0-4751-ADA9-E74C0358D29B
wdtn:P698
n12:28209331
wdt:P698
28209331
p:P1433
wds:Q38956663-DBBF7F85-EE02-4B03-ACB6-159B90CE88F4
wdt:P1433
wd:Q15755067
p:P433
wds:Q38956663-D72DDA23-A543-4794-AA93-3F759F28371E
p:P478
wds:Q38956663-E8FF439A-19F0-4F3B-BFCB-E1B2A8A6B7A1
wdt:P433
4
wdt:P478
16
p:P356
wds:Q38956663-32997B9C-7A24-4801-AA34-23CA97D4E010
wdtn:P356
n10:S1474-4422(17)30007-8
wdt:P356
10.1016/S1474-4422(17)30007-8
p:P8608
wds:Q38956663-C3D0F80E-CAAE-472E-9808-F81EF950569B
wdt:P8608
release_4tonhewgpnhatatstqdajqdycu